Simrati Kaul

1.1k total citations
8 papers, 268 citations indexed

About

Simrati Kaul is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology. According to data from OpenAlex, Simrati Kaul has authored 8 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Cardiology and Cardiovascular Medicine, 3 papers in Internal Medicine and 3 papers in Epidemiology. Recurrent topics in Simrati Kaul's work include Urinary Tract Infections Management (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers) and Medication Adherence and Compliance (2 papers). Simrati Kaul is often cited by papers focused on Urinary Tract Infections Management (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers) and Medication Adherence and Compliance (2 papers). Simrati Kaul collaborates with scholars based in United States, Germany and United Kingdom. Simrati Kaul's co-authors include ‏Mohammed ‏Khashab, Alan C. Fisher, James B. Kahn, Janet Peterson, Howard Klausner, Patricia D. Brown, Mairéad G. McNamara, Hanno Riess, Peter Wildgoose and Ujjwala Vijapurkar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Urology.

In The Last Decade

Simrati Kaul

6 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simrati Kaul United States 6 203 92 76 53 45 8 268
Tarun Bhagnani United States 9 75 0.4× 9 0.1× 35 0.5× 46 0.9× 50 1.1× 16 331
Konstantinos Manolas Greece 8 161 0.8× 62 0.7× 30 0.4× 15 0.3× 30 0.7× 13 342
Bart Knottnerus Netherlands 8 167 0.8× 52 0.6× 76 1.0× 28 0.5× 5 0.1× 30 250
A Arscott United Kingdom 5 197 1.0× 79 0.9× 89 1.2× 40 0.8× 1 0.0× 8 276
F.X.S. Emmanuel United Kingdom 6 94 0.5× 47 0.5× 14 0.2× 7 0.1× 44 1.0× 8 314
Barbara Weisinger United States 6 164 0.8× 10 0.1× 35 0.5× 50 0.9× 205 4.6× 8 352
Jerry Ruley United States 5 292 1.4× 359 3.9× 191 2.5× 7 0.1× 14 0.3× 7 433
C Lagarde France 9 26 0.1× 28 0.3× 6 0.1× 6 0.1× 26 0.6× 17 217
Alfonso Gutiérrez‐Macías Spain 8 72 0.4× 11 0.1× 1 0.0× 48 0.9× 52 1.2× 19 221
C. Andrew DeAbate United States 9 244 1.2× 4 0.0× 7 0.1× 6 0.1× 112 2.5× 12 380

Countries citing papers authored by Simrati Kaul

Since Specialization
Citations

This map shows the geographic impact of Simrati Kaul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simrati Kaul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simrati Kaul more than expected).

Fields of papers citing papers by Simrati Kaul

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simrati Kaul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simrati Kaul. The network helps show where Simrati Kaul may publish in the future.

Co-authorship network of co-authors of Simrati Kaul

This figure shows the co-authorship network connecting the top 25 collaborators of Simrati Kaul. A scholar is included among the top collaborators of Simrati Kaul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simrati Kaul. Simrati Kaul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
2.
3.
Khorana, Alok A., Mairéad G. McNamara, Ajay K. Kakkar, et al.. (2020). Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. SHILAP Revista de lepidopterología. 4(2). e107–e112. 12 indexed citations
4.
Vadhan‐Raj, Saroj, Mairéad G. McNamara, Marino Venerito, et al.. (2020). Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study. Cancer Medicine. 9(17). 6196–6204. 22 indexed citations
5.
Vadhan‐Raj, Saroj, Mairéad G. McNamara, Marino Venerito, et al.. (2019). Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.. Journal of Clinical Oncology. 37(15_suppl). 4016–4016. 8 indexed citations
6.
7.
Peterson, Janet, Simrati Kaul, ‏Mohammed ‏Khashab, Alan C. Fisher, & James B. Kahn. (2007). Identification and Pretherapy Susceptibility of Pathogens in Patients with Complicated Urinary Tract Infection or Acute Pyelonephritis Enrolled in a Clinical Study in the United States from November 2004 Through April 2006. Clinical Therapeutics. 29(10). 2215–2221. 26 indexed citations
8.
Klausner, Howard, Patricia D. Brown, Janet Peterson, et al.. (2007). A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Current Medical Research and Opinion. 23(11). 2637–2645. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tarun Bhagnani Breakdown of academic impact, for papers by Konstantinos Manolas Breakdown of academic impact, for papers by Bart Knottnerus Breakdown of academic impact, for papers by A Arscott Breakdown of academic impact, for papers by F.X.S. Emmanuel Breakdown of academic impact, for papers by Barbara Weisinger Breakdown of academic impact, for papers by Jerry Ruley Breakdown of academic impact, for papers by C Lagarde Breakdown of academic impact, for papers by Alfonso Gutiérrez‐Macías Breakdown of academic impact, for papers by C. Andrew DeAbate
Rankless by CCL
2026